Agenus Inc.

NASDAQ:AGEN

Biotechnology

Healthcare
$6.40 -0.17%

-$0.01 today

Market cap
$289.58M
Beta
1.54
P/E (TTM)
1.7
EPS (TTM)
$1.70
52W Low $2.71High $7.34

Volume 0.88M

Average 0.82M

AGEN Debt Repayment

Cash used to repay borrowings during the period.

Agenus Inc.NASDAQ: AGEN

Debt Repayment · Q1 FY2026 · quarter ended Mar 2026

Debt repayment growth accelerates

Q1 FY2026 debt repayment of $8.44M (cash outflow) rose 204.6% year over year, ahead of the -104.0% change in trailing-twelve-month debt repayment.

Context

  • Debt repayment amounted to 2.1% of revenue in FY2025, down 7.1 pp from a year earlier.
  • Debt repayment increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +204.6% holds above the trailing-twelve-month pace of -104.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$8.44M-220.4% QoQ
Last fiscal yearDec 2025
$2.35M-75.3% YoY
LTMMar 2026
-$3.32M-104.0% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+204.6%——
1 year-75.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
2.35M USD
Year-over-year change
-75.3%

Debt Repayment vs competitors

How AGEN compares with its peers on the latest reported figures

  • AGEN's LTM Mar 2026 debt repayment of $3.32M is the 3rd largest of the 10 companies compared; the peer median is $0.
  • Its year-over-year change of -104.0% is the 2nd highest of 3, against a peer median of -1613350.0%.
  • Debt repayment amounts to 2.7% of revenue for AGEN, versus a peer median of 0.0%.
AGEN Competitors Peer median
Debt Repayment for AGEN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PLRXPliant Therapeutics, Inc.LTM Mar 2026$32.27M -3226800.0%——
TTRXTurn Therapeutics Inc.LTM Mar 2026$6.72M ———
AGENAgenus Inc.LTM Mar 2026$3.32M -104.0%—2.7%
IRDOpus Genetics, Inc.LTM Mar 2026$1M ——8.3%
HURATuHURA Biosciences, Inc.LTM Mar 2026$408.78K ———
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$0 ———
FATEFate Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$0 ———
SEERSeer, Inc.LTM Mar 2026$0 ——0.0%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$0 +100.0%——
Peer median (excluding AGEN) $0-1613350.0%—0.0%

Competitors are the stored peer set for AGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(28.72M)(230.66M)(257.44M)(232.27M)(232.27M)
Depreciation & Amortization6.79M6.95M13.59M13.34M13.34M
Deferred Income Tax00000
Stock-Based Compensation19.58M18.34M22.87M17.39M17.39M
Change in Working Capital(9.74M)24.08M10.76M32.6M27.33M
Accounts Receivables(394K)122K(23.46M)25.34M(1.73M)
Inventory00000
Accounts Payables10.82M6.49M21.37M2.01M23.5M
Other Working Capital(20.17M)17.47M12.85M5.25M5.56M
Other Non-Cash Items22.25M5.92M(13.98M)10.62M15.89M
Operating Cash Flow10.15M(175.37M)(224.2M)(158.32M)(158.32M)
Capital Expenditures(33.81M)(53.06M)(9.95M)(576K)(576K)
Acquisitions (Net)0(2.92M)000
Purchases of Investments(14.99M)(24.63M)(20.04M)00
Sales of Investments025M30.03M579K579K
Other Investing Activities5.66M22M3.36M24K24K
Investing Cash Flow(43.15M)(33.61M)3.4M27K27K
Debt Repayment(1.32M)(490K)(8.93M)9.52M2.35M
Common Stock Issued220.65M99.21M133.16M38.82M36.31M
Common Stock Repurchased(1.65M)(3.79M)(5.17M)0(87K)
Dividends Paid00000
Other Financing Activities7.59M898K807K74.5M84.27M
Financing Cash Flow225.26M95.83M119.87M122.84M122.84M
Effect of Forex Changes(164K)(104K)(628K)(260K)(260K)
Net Change in Cash192.1M(113.26M)(101.56M)(35.71M)(35.71M)
Free Cash Flow(23.67M)(228.44M)(234.16M)(158.89M)(158.89M)

Agenus Inc.

NASDAQ:AGEN

Intrinsic Alpha fair value

Locked

Current Price

$6.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.